title: Effect of obesity on patient-reported outcomes in sarcoidosis.
abstract: OBJECTIVE
  To assess the impact of high body mass index (BMI) on patient-reported outcomes in sarcoidosis patients and healthy persons.
  
  
  METHODS
  In this case-control study, we investigated symptoms of fatigue and dyspnoea, health status, BMI and spirometric tests in 184 sarcoidosis patients and the same number of sex- and age-matched healthy subjects. Fatigue was assessed using the fatigue scale (FS), dyspnoea was determined by the baseline dyspnoea index (BDI) and health status was measured using the respiratory-specific St George's Respiratory Questionnaire (SGRQ).
  
  
  RESULTS
  There were significantly more subjects with increased BMI (≥25 kg/m(2)) among the sarcoidosis patients than among the healthy volunteers ((2) 37.675, P < 0.01). Sarcoidosis patients also had a greater probability of having a higher BMI (P < 0.01, OR 1.18, 95%CI 1.071.3). We found significantly lower BDI scores and forced expiratory volume in 1 s/forced vital capacity, as well as higher total SGRQ and total FS scores in sarcoidosis patients than in healthy individuals (P < 0.01 for all differences).
  
  
  CONCLUSIONS
  Sarcoidosis significantly reduces patients' health status, both independently and also due to increased BMI. Reduction in BMI may contribute to improved spirometry results and health status of patients with sarcoidosis.
authors.affiliation: Department of Clinical Management, PPD Serbia, Serbia, 11010 Belgrade, Serbia. bgvozden@verat.net
authors.forename: B S
authors.initials: BS
authors.lastname: Gvozdenovic
authors.forename: V
authors.initials: V
authors.lastname: Mihailovic-Vucinic
authors.forename: M
authors.initials: M
authors.lastname: Vukovic
authors.forename: E E
authors.initials: EE
authors.lastname: Lower
authors.forename: R P
authors.initials: RP
authors.lastname: Baughman
authors.forename: A
authors.initials: A
authors.lastname: Dudvarski-Ilic
authors.forename: V
authors.initials: V
authors.lastname: Zugic
authors.forename: S
authors.initials: S
authors.lastname: Popevic
authors.forename: J
authors.initials: J
authors.lastname: Videnovic-Ivanov
authors.forename: S
authors.initials: S
authors.lastname: Filipovic
authors.forename: M
authors.initials: M
authors.lastname: Stjepanovic
authors.forename: M
authors.initials: M
authors.lastname: Omcikus
mesh_terms: D000328:Adult; D015992:Body Mass Index; D016022:Case-Control Studies; D016009:Chi-Square Distribution; D004417:Dyspnea / Q000209:etiology; D005221:Fatigue / Q000209:etiology; D005260:Female; D005541:Forced Expiratory Volume; D006304:Health Status; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016015:Logistic Models; D008168:Lung / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009765:Obesity / Q000150:complications* / Q000175:diagnosis; D016017:Odds Ratio; D011237:Predictive Value of Tests; D011379:Prognosis; D012307:Risk Factors; D017565:Sarcoidosis, Pulmonary / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology; D055771:Serbia; D013147:Spirometry; D011795:Surveys and Questionnaires; D014797:Vital Capacity
chemical_list: D007166:Immunosuppressive Agents